文献速递其他结缔组织病

托法替布治疗抗MDA5抗体阳性皮肌炎难治性间质性肺疾病

Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.
PubMed 文献 · Rheumatology (Oxford) · 2018-01-01

本文报告5例抗MDA5抗体阳性皮肌炎相关难治性快速进展型间质性肺疾病患者,在高三尖杉酯碱方案(糖皮质激素、环孢素A、环磷酰胺)失败后加用托法替布10 mg/日。5例中3例存活、2例死亡;托法替布组生存率显著优于托法替布前免疫抑制治疗的历史对照。患者出现包括病毒感染在内的复杂不良事件。

要点

  • 抗MDA5抗体阳性DM-ILD的三个不良预后因素:治疗前血清铁蛋白>1000 ng/ml、治疗前全部六个肺野磨玻璃影、治疗中肺部浸润恶化。
  • 5例具备全部三个预后因素且三联治疗失败者加用托法替布后3例存活、2例死亡。
  • 托法替布组生存率显著优于托法替布前免疫抑制治疗的历史对照。

核心结论

  • 托法替布联合治疗可能具有控制难治性抗MDA5抗体阳性DM-ILD的潜力。

研究设计与样本

  • 病例系列:5例抗MDA5抗体阳性DM-ILD患者对高三尖杉酯碱方案(糖皮质激素、环孢素A、环磷酰胺)无效后加用托法替布10 mg/日。
  • 为识别不良预后因素,回顾分析15例连续抗MDA5抗体阳性DM-ILD患者(7例存活、8例死亡)在托法替布诱导前的数据。

主要发现

  • 识别出三个不良预后因素:治疗前血清铁蛋白>1000 ng/ml、治疗前全部六个肺野磨玻璃影、治疗中肺部浸润恶化。
  • 具备全部三个因素并接受三联治疗的6例患者在托法替布治疗前全部死亡。
  • 5例具备全部三个预后因素且三联治疗失败者接受托法替布联合治疗,其中3例存活、2例死亡。
  • 接受托法替布者的生存率显著优于托法替布前接受免疫抑制治疗的历史对照。
  • 接受托法替布者出现复杂不良事件,尤其病毒感染。

关键数值与推荐

  • 不良预后因素:治疗前血清铁蛋白>1000 ng/ml。
  • 不良预后因素:治疗前全部六个肺野磨玻璃影。
  • 不良预后因素:治疗中肺部浸润恶化。
  • 托法替布剂量:10 mg/日。

临床怎么用

  • 对于具备全部三个不良预后因素且对高三尖杉酯碱方案(糖皮质激素、环孢素A、环磷酰胺)无效的抗MDA5抗体阳性DM-ILD患者,加用托法替布10 mg/日可能具有控制疾病的潜力。
  • 接受托法替布治疗者出现复杂不良事件,尤其病毒感染。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to determine the outcome of combination therapy with tofacitinib (TOF) in a case series of refractory rapidly progressive interstitial lung disease (ILD) associated with anti-melanoma differentiation-associated 5 gene (MDA5) antibody-positive (Ab+) DM. Patients who had poor prognostic factors and failed to respond to immunosuppressive therapy were selected for TOF treatment. METHODS: Five patients with anti-MDA5 Ab+ DM-ILD who failed to respond to triple therapy with high dose glucocorticoids, CSA and CYC were given additional TOF (10 mg/day). To identify the poor prognostic factors, data from 15 consecutive patients (seven survived and eight died) with anti-MDA5 Ab+ DM-ILD before induction of TOF were analysed. RESULTS: Three poor prognostic factors were identified: serum ferritin level >1000 ng/ml before therapy; ground-glass opacities in all six lung fields before therapy; and worsening of pulmonary infiltrates during therapy. All six patients who had all of the three factors and received triple therapy died before TOF therapy. There were five patients who had all of the three prognostic factors and failed to respond to triple therapy, but were able to receive the combination therapy with TOF; among them, three survived and two died. The survival rate of patients who received TOF was significantly better than that of the historical controls with immunosuppressive therapy before TOF. The patients who received TOF experienced complicated adverse events, particularly viral infection. CONCLUSION: Combination therapy with TOF might have the potential to control refractory anti-MDA5 Ab+ DM-ILD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Kurasawa K, Arai S, Namiki Y, et al. Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis. Rheumatology (Oxford). 2018. PMID: 30060040. doi:10.1093/rheumatology/key188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。